VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd

Bullboard Posts

Post by sammydlon May 17, 2018 3:05pm

137 Views

Post# 28047904

Massive share price gain coming.

Very undervalued play, shot up same time last year from 0.17 to 0.29, Q1 results in next week will be even bigger then last's year's results.

bmoe80 wrote:
Stock up, average down. Good buy in price right now. Meeting is next Thursday and Q1 results will be announced by then or on that day. From what I gather, it should be one of the best quarters, we should also be seeing some more positive numbers/contracts coming through. Last year this time stock ran up to 0.29 on the revenue growth results, hopefully we see it testing this January's highs of 0.21 and better.

Market hasn't taken into account it's growing revenue stream over the past year, or einsteinium/cryptocurrency pontential, or potential for "Voxtel in the political arena its planned launch in crypto contributions in the Fall of 2018.

Definitely very undervalued at current stock price, especially compared to similiar stocks like MOS which had 2017 revenues of less then $3 milliion compared to ATW's $12 million, but trades at a much higher market cap of $25 million. This stock should be trading well about the 0.30/0.40's.